Concepedia

Publication | Open Access

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

DOIFull Paper Access

1.7K

Citations

25

References

2010

Year

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil, P. Le Coutre, Gabriel Étienne, Clarisse Lobo, Ricardo Pasqüini, Richard E. Clark, Andreas Hochhaus, Timothy P. Hughes,
New England Journal of Medicine

Abstract

Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.)

References

YearCitations

Page 1